



## Erratum

To cite this article: (2009) Erratum, Expert Opinion on Investigational Drugs, 18:6, 873-873, DOI: [10.1517/13543780903035108](https://doi.org/10.1517/13543780903035108)

To link to this article: <https://doi.org/10.1517/13543780903035108>



Published online: 25 May 2009.



Submit your article to this journal [↗](#)



Article views: 241



View related articles [↗](#)

In the Drug Evaluation “Belinostat: a new broad acting antineoplastic histone deacetylase inhibitor” by Gimsing P, published in the April 2009 issue of *Expert Opinion on Investigational Drugs* (*Expert Opin. Investig. Drugs* (2009) 18(4):501-508), the declaration of interest statement on page 507 should have read as follows:

P Gimsing was a consultant for TopoTarget when the Phase I and II trials on malignant hematological diseases were planned 3 years ago and was the principal investigator of these trials, but has had no such position since then and no other connections.

The author, editors and publisher sincerely regret any inconvenience that these omissions may have caused.



